ESTD vs. VATS for Upper Gastrointestinal Submucosal Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01768104|
Recruitment Status : Unknown
Verified December 2011 by Nanfang Hospital of Southern Medical University.
Recruitment status was: Recruiting
First Posted : January 15, 2013
Last Update Posted : January 15, 2013
|Condition or disease||Intervention/treatment||Phase|
|Upper Gastrointestinal Submucosal Tumors (SMTs) Gastrointestinal Stromal Tumors (GISTs) Leiomyoma||Procedure: ESTD Procedure: VATS||Not Applicable|
Most upper gastrointestinal submucosal tumors (SMTs), especially the gastrointestinal stromal tumors (GISTs) and leiomyoma, are regarded as benign if they are less than 3cm in size. Thus, it has been suggested that patients should receive periodic endoscopic follow-up in case of gradual changes in size; however this can be stressful and troublesome for patients. Nevertheless, some of these tumors do have a malignant potential, and management by periodic endoscopic surveillance may lead to delayed diagnosis of malignancy. Therefore, it is necessary to remove the SMTs.
To date, several approaches have been used for the treatment of upper gastrointestinal SMTs, including open, thoracoscopic and laparoscopic surgery, and endoscopic approaches such as band ligation, endoscopic submucosal dissection (ESD), and endoscopic full-thickness resection (EFR). However, the surgical approaches are invasive with a longer hospital stay and greater cost, while the endoscopic approaches were limited by technical difficulty, incomplete resections and risk of perforation.
Recently, the technique of peroral endoscopic myotomy (POEM) for esophageal achalasia was introduced, a procedure in which a submucosal tunnel is created to expose and dissect the circular muscle of the esophagus. Inspired by the POEM approach, we have successfully used a similar method, endoscopic submucosal tunnel dissection (ESTD), to resect SMTs in upper gastrointestinal.
However, the long-term efficacy and safety of ESTD were not determined, and there was no prospective study compared the ESTD with other conventional approaches. Therefore, we plan to conduct this prospective randomized controlled trial, aim to determine the efficacy and safety of ESTD, compared with the pneumatic dilation, in the treatment of upper gastrointestinal SMTs originating from the muscularis propria layer .
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Endoscopic Submucosal Tunnel Dissection Versus Video-assisted Thoracoscopic Surgery for Upper Gastrointestinal Submucosal Tumors: a Prospective Randomized Controlled Trial|
|Study Start Date :||December 2011|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2013|
Endoscopic submucosal tunnel dissection (ESTD) for patients with upper gastrointestinal submucosal tumors (SMTs)
(Gong W et al. ESTD for upper gastrointestinal submucosal tumors… Endoscopy 2012; 44: 231-235)
Active Comparator: VATS
Video-assisted thoracoscopic surgery (VATS) for patients with upper gastrointestinal submucosal tumors (SMTs)
(Luh et al. World Journal of Surgical Oncology 2012, 10:52)
- En bloc resection [ Time Frame: During the operation ]The En bloc resection was defined as a one-piece resection of the entire lesion without fragmentation
- Curative resection [ Time Frame: From date of randomization until the date of pathological diagnosis, an expected average of 7 days ]The curative resection was defined as the resected specimen with vertical and lateral margins free of neoplasia in pathological diagnosis.
- Procedure related complication [ Time Frame: From date of operation until the occurrence of the procedure related complication, which most occur within 7 days after operation, assessed up to 2 years ]Perforation, Delayed bleeding, Pneumothorax, Subcutaneous emphysema, Anastomotic leak, etc.
- Short-term morbidity [ Time Frame: From date of randomization until the date of death from any cause, assessed up to 3 months ]Any cause death
- Local recurrence [ Time Frame: From date of randomization until the follow-up ended, assessed up to 2 years ]Local recurrence was defined as endoscopic or histological diagnosis of cancer at the resected site in follow-up
- Quality of life [ Time Frame: From date of randomization until the follow-up ended, assessed up to 2 years ]Patients will complete the quality-of-life questionnaires (the Medical Outcomes Study 36-Item Short-Form Health Survey, SF-36) for assessing quality of life
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01768104
|Contact: Wei Gong, M.D.||+86 email@example.com|
|Nanfang Hospital of Southern Medical University||Recruiting|
|Guangzhou, Guangdong, China, 510515|
|Contact: Xiaobing Cui, M.D. +86 13631312723 firstname.lastname@example.org|
|Principal Investigator:||Wei Gong, M.D.||Department of Gastroenterology, Nanfang Hospital of Southern Medical University|